Date: 2017-03-02
Type of information: Nomination
Compound: member of the board of directors
Company: Bioverativ (USA - MA)
Therapeutic area: Rare diseases - Genetic diseases - Hematological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On March 2, 2017, Bioverativ announced that Anna Protopapas has been appointed to the company’s board of directors. Ms. Protopapas has more than 20 years of experience in the biopharmaceutical industry, including her current role as President, Chief Executive Officer and member of the board of directors of Mersana Therapeutics. Previously, Ms. Protopapas was a member of the Executive Committee of Takeda Pharmaceutical and held various senior management positions at the company, including President of Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda focused on oncology.
- This appointment brings Bioverativ’s total number of directors to five, four of whom are independent. In addition to John Cox, the current members of the board include:
- Brian Posner (Chairman), the President of Point Rider Group, a consulting and advisory services firm within the financial services industry and a private investor since 2008. Mr. Posner currently serves on the boards of directors of Biogen Inc. and Arch Capital Group. and is a trustee of the AQR Funds. Mr. Posner brings substantial experience as a leading institutional investment manager and advisor, and significant management and financial expertise to his leadership of the Bioverativ board.
- Alexander Denner, Ph.D. (director), the founding partner and Chief Investment Officer of Sarissa Capital Management, a registered investment advisor, which he founded in 2012. Sarissa Capital focuses on improving the strategies of companies to enhance shareholder value. Dr. Denner also serves as a director of Biogen Inc. and The Medicines Company. Dr. Denner has a strong background overseeing the operations, capital allocation and research and development of healthcare companies and evaluating corporate governance matters. He also has extensive experience as an investor, particularly with respect to healthcare companies, and has broad healthcare-industry knowledge.
- Louis Paglia (director), the founding member of Oakstone Capital, a private investment firm, and founder of Customer Choice , a data analytics company serving the electric utility industry. He currently serves as a member of the board of directors of Arch Capital Group. Mr. Paglia has a strong financial background, with experience in investment banking and extensive executive management and operating experience in publicly-held companies.
Financial terms:
Latest news:
Is general: Yes
